Rebecca Matro, MD
Gastroenterology · Portland, ORNPI 1043484405
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,192 of the $153,564 with a category attached, or 73.7%. 20 manufacturers reported payments, led by Johnson & Johnson at 56.7% of the total. Among gastroenterology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $370.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$87K
- AbbVie$58K
- Pfizer$5K
- Takeda Pharmaceuticals U.S.A., Inc.$631
- Bristol Myers Squibb$542
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$528
- plus $2K from 14 others
Across 2 payments — averaging $41.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$83
What the payments were for
- Consulting fees$18,79512%
- Speaking & faculty fees$113,19274%
- Travel & lodging$11,3907%
- Food & beverage$10,1877%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 97 | $87,018 |
| AbbVie | 168 | $57,963 |
| Pfizer | 6 | $5,032 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $631 |
| Bristol Myers Squibb | 20 | $542 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $528 |
| Janssen Scientific Affairs, LLC | 5 | $441 |
| Regeneron Healthcare Solutions, Inc. | 12 | $278 |
| Merck | 14 | $264 |
| Sanofi | 9 | $261 |
| Lilly USA, LLC | 5 | $129 |
| Phathom Pharmaceuticals, Inc. | 6 | $102 |
| Ardelyx, Inc. | 5 | $75 |
| QOL Medical, LLC | 3 | $67 |
| Braintree Laboratories, Inc. | 4 | $62 |
| Boehringer Ingelheim | 3 | $58 |
| Redhill Biopharma Inc. | 2 | $55 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,564 in reported general payments places this provider in the 95th percentile of 220 gastroenterology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 28 | $529,782 |
| StelaraUstekinumab | 11 | $295,010 |
| RinvoqUpadacitinib | 29 | $214,930 |
| Mesalamine | 53 | $28,239 |
| LinzessLinaclotide | 19 | $9,904 |
| MotegrityPrucalopride Succinate | 12 | $6,184 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 55 | $3,743 |
| Lubiprostone | 12 | $1,690 |
| Pantoprazole Sodium | 23 | $410 |
| Omeprazole | 32 | $346 |
| Esomeprazole Magnesium | 14 | $223 |
| MethotrexateMethotrexate Sodium | 11 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $87,018 | $295,01011 claims |
| AbbVieRinvoq, Linzess | $57,963 | $224,83448 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $631 | $6,18412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 220 gastroenterology providers in Oregon.
Other gastroenterology in Portland
- Donald LumPortland$320K
- Ian HolmesPortland$102K
- Amy ZhuPortland$72K
- Gregory CotePortland$58K
- Emily JonicaPortland$49K
- Rebecca FauselPortland$29K
- Anil SharmaPortland$14K
- Harry BrayPortland$11K
- Kaveh SharzehiPortland$6K
- Willscott NauglerPortland$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.